vimarsana.com
Home
Live Updates
Bayer cancels asundexian phase III study programme : vimarsana.com
Bayer cancels asundexian phase III study programme
Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor. Read more at straitstimes.com.
Related Keywords
Xia Fxia
,
Data Monitoring Committee
,
Reuters
,
Independent Data Monitoring Committee
,
vimarsana.com © 2020. All Rights Reserved.